Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

New Pediatric Labeling Information Database - Detail
  • Print
  • Share
  • E-mail
-
 
Pediatric Labeling Date:  08/22/2019
 
Trade Name:  Tybost
 
Generic Name or Proper Name (*):  cobicistat
 
Indications Studied:  HIV-1 infection in pediatric patients weighing = 35 kg
 
Label Changes Summary:  *Safety and effectiveness co -administered with atazanavir and two nucleoside reverse transcriptase inhibitors for the treatment of HIV-1 infection have been established in virologically suppressed pediatric patients weighing at least 35 kg. *Use for this indication is supported by evidence from adequate and well-controlled studies in adults, and by pharmacokinetic, safety, and virologic data from an open-label trial in virologically suppressed, HIV-1 infected pediatric patients 12 years and older. *Safety through 48 weeks was similar to that in antiretroviral treatment-naïve adults. *Safety and effectiveness in combination with atazanavir in pediatric patients weighing less than 35 kg have not been established. *Safety and effectiveness in combination with darunavir in pediatric patients have not been established. *Information on dosing, PK parameters, adverse reactions, and clinical trial. *Postmarketing study.
 
BPCA(B) and PREA(P):  B,P
 
Sponsor:  Gilead Sciences, Inc.
 
NNPS:  FALSE
 
Therapeutic Category:  Antiviral
 
-
-